Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000203732 | SCV000259971 | uncertain significance | Ataxia-telangiectasia syndrome | 2021-12-22 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ATM protein function. ClinVar contains an entry for this variant (Variation ID: 219864). This variant has not been reported in the literature in individuals affected with ATM-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces isoleucine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 550 of the ATM protein (p.Ile550Arg). |
| Ambry Genetics | RCV000575790 | SCV000668051 | uncertain significance | Hereditary cancer-predisposing syndrome | 2017-01-26 | criteria provided, single submitter | clinical testing | The p.I550R variant (also known as c.1649T>G), located in coding exon 10 of the ATM gene, results from a T to G substitution at nucleotide position 1649. The isoleucine at codon 550 is replaced by arginine, an amino acid with similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |